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Background: We have previously reported an age-related impairment in the serum antibody response to
pandemic (p)2009 H1N1, measured by hemagglutination inhibition assay and ELISA. The present study extends
these observations and evaluates IgG subclass distribution in healthy individuals of different ages vaccinated during
the 2011–2012 season.
Results: The 2011-2012 vaccination season was characterized by a vaccine containing the pandemic (p)2009 H1N1
strain for the third consecutive year. All of our subjects were previously immunized, and therefore seroprotected at
t0. Nevertheless, aging impaired the serum antibody response to H1N1, as antibody titers increased after
vaccination in young and less in elderly individuals. The peak of the response was at day 7 (t7), in contrast with
what is usually seen at day 21–28, suggesting a memory response characterized by the induction of an IgG
subclass with a shorter half-life. We hypothesized that the IgG3 response, with its much shorter half-life, might be
more represented. Antibodies were predominantly of the IgG1 subclass in both age groups, although a robust IgG3
response was also induced and accounted for a significant proportion of the overall response. IgG2 and IgG4
antibodies were at indiscernible levels. We showed a much higher percentage of IgG3 (40–50%) than previously in
the literature (less than 10%). To explain if this was associated with a particular cytokine profile, we measured
H1N1-induced T cell cytokines in vitro and found that IgG3 levels were positively correlated with TNF-α and IL-6.
Moreover, activation-induced cytidine deaminase (AID) mRNA expression, a predictive biomarker of optimal in vivo
vaccine response, was found to significantly correlate with IgG3 and also with IgG1 similar to what we have shown
previously for total IgG.
Conclusions: In the 2011–2012 season, the pandemic (p)2009 H1N1 strain was present in the vaccine for the third
consecutive year and therefore each individual was seroprotected at t0. The peak of the response was at t7,
suggesting a memory response characterized by a robust induction of IgG3, which was associated with TNF-α and
IL-6 production. Both IgG1 and IgG3 responses were decreased by age. AID was confirmed to be a predictive
biomarker of optimal vaccine responses.
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Influenza is associated with morbidity and mortality in
individuals 65 years of age and older, children under
2 years of age and individuals at high risk for complica-
tions from influenza because of other co-morbidities [1].
These complications may include secondary bacterial
infections, exacerbations of pre-existing medical condi-
tions [1,2] and hospitalization which significantly con-
tributes to the development of disability in the elderly
[3] and represent a significant economic burden [4]. In-
fluenza infections every year are associated with approxi-
mately 200,000 estimated hospitalizations and 36,000
deaths in the United States [5].
The effects of influenza vaccination are different in
individuals of different ages [6-8]. Successive annual vac-
cinations increase protection against influenza [9,10].
There is evidence that elderly individuals who have
routinely received the vaccine can still contract the
infection, with secondary complications leading to hos-
pitalization, physical debilitation, exacerbation of under-
lying medical conditions and death [11-13]. However,
influenza vaccines reduce the severity of the infection
and also prevent complications from influenza and
therefore vaccination campaigns targeted to improve
immune functions in elderly individuals are supported.
Immunoglobulin (Ig) G levels are important for anti-
body vaccine responses and the subclass distribution
may be clinically relevant, as suggested by the evidence
that IgG subclass deficiencies are associated with severe
influenza infections in immunocompromised patients
[14]. In humans there are four subclasses of IgG: IgG1,
IgG2, IgG3 and IgG4, which constitute about 65%, 23%,
8%, and 4%, respectively, of the total serum IgG. The
four subclasses differ in structure, half-life and function.
IgG1 and IgG3 are the most important in complement-
fixation and antibody-dependent cellular cytotoxicity,
which have a role in virus neutralization. Previous stu-
dies have shown that the major subclass of IgG detected
in serum after influenza infection or vaccination is IgG1
and then IgG2 [15] or IgG3 [16-20] , but in much lower
amounts. Levels of IgG4 are usually lower than those of
the other subclasses.
Both vaccine and host factors influence the serum IgG
subclass distribution after influenza vaccination. Soluble
peptides preferentially induce IgGl and IgG3 responses
[21,22], whereas natural infection or vaccination with
live and/or inactivated viruses induce predominantly if
not exclusively IgG1 [18,19]. Endogenous cytokines may
also play an important role in regulating Ig isotype pro-
duction. In general, IgG1 is associated with a Th2 profile
and the other subclasses are mainly associated with a
Th1 profile [23].
Aging has been associated with a significant impair-
ment of IgG1, but not IgG3 production [20] and this hasbeen suggested to be one of the causes of the lower in-
fluenza vaccine efficacy in the elderly perhaps due to the
lower half-life of IgG3 antibodies. Other reports showed
no IgG3 response to the vaccine in either young or el-
derly [15,24]. Changes in cytokine profile during se-
nescence have been reported and attributed to changes
in both the innate and the adaptive immune systems
[25-28], which may cause parallel changes in the relative
amounts of the different IgG subclasses produced in re-
sponse to the influenza vaccine.
In the present study we have investigated the effects of
age on serum IgG subclass responses after vaccination
of individuals of different ages with the trivalent inac-
tivated influenza (TIV) vaccine, during the 2011-2012
season. This vaccination season was characterized by a
vaccine containing the pandemic (p)2009 H1N1 strain
for the third consecutive year. We measured the H1N1-
specific response and noticed that the peak of the re-
sponse was at t7 which we hypothesized could be due to
both increased IgG3 serum levels as well as to the re-
stimulation of a memory response. IgG1 was the main
IgG subclass detected in serum after influenza vacci-
nation, followed by IgG3, confirming previously pub-
lished data [16-20], but there was much more, up to
50%, IgG3 in our studies. Moreover, aging decreased
both IgG1 and IgG3 serum levels, as opposed to what
has been previously shown [20]. In order to evaluate the
cytokine profile induced by the vaccine and associated
with these elevated IgG3 serum levels, we stimulated
PBMC with H1N1 and found significant correlations
between IgG3 levels and TNF-α and IL-6 production.
We also measured activation-induced cytidine deami-
nase (AID), a biomarker of optimal antibody responses,
and made correlations with IgG1 and IgG3 serum levels.
AID is essential for DNA cleavage required for class
switch recombination (CSR) and somatic hypermutation
(SHM) which are crucial for the generation of high af-
finity antibodies and robust humoral immunity [29,30].
CSR and SHM occur in germinal center B cells in re-
sponse to both T-dependent and T-independent stimuli
[31,32]. AID triggers CSR and SHM by deaminating cy-
tosines in the variable and switch regions of the Ig locus,
converting them to uracils, and the resulting mismatches
are recognized by specific enzymes and excised, leading
to DNA double strand breaks [33]. Our results herein
show that AID is positively correlated with IgG3 anti-
bodies, and also with IgG1, similar to what we have
shown previously for total IgG.
Results and discussion
Characteristics and serological profile of the subjects in
the study
Demographic and basic information on the participants
(age, gender, race, ethnicity) and their serological profiles
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Figure 1 Decreased serum response to the influenza vaccine in
the elderly. Sera isolated before (t0) and after vaccination (t7 and
t28) were evaluated in HAI. Results are expressed as reciprocal of the
titers. Non-parametric analyses were calculated by Mann-Whitney
test (two-tailed), using GraphPad Prism 5 software. See text for
differences between young and old groups. The numbers of
individuals are given in Table 1.
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CRP as well as cytomegalovirus (CMV) positivity. Results
show significantly higher levels of serum TNF-α, IL-6 and
CRP in elderly as compared to young individuals. The per-
centage of CMV-positive individuals was also significantly
higher in the elderly group.
Age effects on in vivo vaccine responses
We measured the in vivo response to the vaccine using
the HAI assay which is the best correlate for vaccine
protection. In addition, we also measured the serum re-
sponse by ELISA and we have previously shown that it
completely correlates with HAI [34]. We tested the puri-
fied proteins from the 3 viral strains present in the vac-
cine preparation: H1N1, H3N2 and B. Here, we only
present data on H1N1 because the response to H3N2
and B was much lower and we wanted to measure the
memory response to the H1N1 antigen given the third
time. The response to the antigen H3N2 followed the
same pattern as that of H1N1, whereas the response to
the antigen B did not show age-related differences bet-
ween young and elderly individuals (see below). Results
in Figure 1 show similar titers in young and elderly indi-
viduals at t0, due to the fact that all individuals were vacci-
nated in the previous 2 seasons with a vaccine containing
the same H1N1 p2009 swine-origin strain (p = 0.41). Ti-
ters increased significantly in young and to a lesser extent
in elderly individuals at t7, but at t28 increased signifi-
cantly only in young individuals. At t7 and t28, titers in
young and in elderly individuals were significantly differ-
ent (p = 0.03 and p = 0.001, respectively). Nevertheless, all
subjects had titers at t0 ≥1:40, suggesting protection from
potential influenza infections. This result is different from
what we and others have previously shown, where the op-
timal response to vaccination in both young and elderly
individuals was at t28 and was sustained until 12 weeks
post-vaccination [35,36].Table 1 Demographic and serological characteristics of
the participants
Young Elderly
Participants (n) 35 25
Age (mean years ± SE) 40 ± 3 69 ± 5b
Gender (M/F) 12/23 11/14
Race (W/B) 20/15 15/10
Ethnic Categories (Hispanic/Non Hispanic) 14/21 8/17
CMV (% positive individuals) 22 78b
TNF-α (pg/ml) 6 ± 1 13 ± 4a
IL-6 (pg/ml) 44 ± 18 101 ± 33b
CRP (pg/ml) 640 ± 95 895 ± 57b
Young: 20-59 years, Elderly: ≥60 years.
ap < 0.01, bp < 0.05.In young individuals, the H3N2-specific response in-
creased at t7 and t28 as compared to t0. Titers were:
210 ± 42 (t0), 833 ± 165 (t7) and 668 ± 165 (t28). Differ-
ences between t0 and t7/t28 were statistically significant
(p < 0.05 both). In elderly individuals, the response to
H3N2 did not increase at t7 or at t28 as compared to t0.
Titers were: 232 ± 49 (t0), 374 ± 101 (t7) and 357 ± 64
(t28). Therefore, at the peak of the response (t7) the
H3N2-specific titers were significantly decreased by
aging (p < 0.05). The B-specific response was compar-
able in young versus elderly individuals at t0 (210 ± 55
versus 275 ± 66) and did not increase after vaccination
at t7 (273 ± 48 versus 187 ± 42) or t28 (301 ± 84 versus
297 ± 59).
The fact that in both young and elderly individuals the
antibody titers didn’t increase or stay sustained after t7
suggested stimulation of an existing memory response to
this vaccine and also that an IgG subclass with a shorter
half-life may have been induced. We therefore measured
total IgG and the 4 different IgG subclasses at t7 and t28
by H1N1-specific ELISA. Only antibodies of IgG1
and IgG3 subclasses were detected in serum. Results
in Figure 2A show that aging significantly impairs
IgG serum levels at t7 and t28, and we have already
shown this for t28 [34] and responses are lower at t28
for young (p = 0.045) as well as for elderly individuals
(p = 0.041). We measured the subclass responses here
by ELISA because we cannot measure the subclasses by
HAI and we have previously shown that the HAI and
ELISA responses completely correlate [34]. Aging also
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Figure 2 Decreased induction of IgG, IgG1 and IgG3 by the influenza vaccine in the elderly. A. Sera isolated before (t0) and after
vaccination (t7 or t28) were collected and evaluated in H1N1-specific IgG, IgG1 and IgG3 ELISA. Data are expressed as OD at t7 or t28 minus OD
at t0. All values here demonstrate a positive response. Data would look similar if only OD at t7 or t28 are shown. Mean comparisons between
groups were performed by Mann-Whitney test (two-tailed), using GraphPad Prism 5 software. P values (two-tailed) are indicated in each graph.
The numbers of individuals are given in Table 1. B. Individual IgG1 and IgG3 responses at t7 and t28 are shown. The numbers of individuals are
given in Table 1.
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http://www.immunityageing.com/content/10/1/14significantly decreases IgG1 serum levels at t7 and t28
and IgG3 serum levels at t7 and responses are lower at
t28 for young (p = 0.035) and also for elderly individuals
(p = 0.042). We found that the peak response was at t7
for both subclasses, and also for IgG, and we expected thiskinetic for IgG3 but not for IgG1, due to the different
half-lives of the 2 subclasses (7 and 21 days, respectively).
Antibodies induced by vaccination were predominantly of
the IgG1 subclass in both age groups, although a robust
IgG3 response was also induced and accounted for a
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the influenza vaccine in both age groups. The percentage
of individuals with a predominant IgG1 response was 70%
and 62% in young and elderly, respectively, whereas that
of individuals with a predominant IgG3 response was 12%
and 25%, in young and elderly, respectively. The percent-
age of individuals with equal amounts of IgG1 and IgG3
was 18% and 13% in young and elderly, respectively. The
decrease in serum levels of IgG1 and IgG3 subclasses at
t28 as compared to t7 is shown in Figure 2B for each in-
dividual and this decrease is significant only for young
(p = 0.025) but not for elderly individuals (p = 0.071).
These results suggest that the reason why the serum re-
sponse did not increase or remained sustained at t28
cannot exclusively depend on the induction of an IgG
subclass with a shorter half-life (IgG3).
We hypothesize that the vaccine composition in the
2010-2011 and 2011-2012 seasons induced a higher
IgG3 serum response, as samples that we have tested in
previous seasons, including the p2009 season, induced
almost no IgG3. In particular, pH1N1-specific IgG3 were
detectable only at t7. ELISA values, expressed as OD at
t7 minus OD at t0, were: 0.11 ± 0.01 and 0.08 ± 0.01 in
young versus old. Because the total IgG serum response
was higher due to repeated immunizations (see Figure 1),
the absolute amount as well as the percentage of the re-
sponse was increased for IgG3. These studies suggest
that both the humoral and cellular immune response to
particular vaccines should be more completely followed
and correlated with protection. The high IgG3 levels in
the 2011-2012 season were not deleterious, as the IgG1
levels were also high and the vaccine likely generated a
good T cell response. In fact, according to Centers for
Disease Control and Prevention (CDC) the 2011-2012
season set a new record for the lowest peak for influenza-
like-illness ever recorded [37].
We also measured during the 2011-2012 season the
IgG serum response to the other 2 antigens present
in the vaccine: H3N2 and B by ELISA. Results0.0 0.2 0.4 0.6 0.8 1.0
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Figure 3 Pro-inflammatory cytokine production in cultured PBMC is p
Frozen PBMC (106 cells/ml), isolated from the peripheral blood at t0, were
time, supernatants were collected and analyzed in ELISA for cytokine produ
Prism 5 software. P values are indicated for each graph. The numbers of inindicate that at the peak of the response (t7) the
H3N2-specific IgG response was significantly decreased
by aging (0.321 ± 0.046 and 0.125 ± 0.013, in young versus
elderly, respectively, p < 0.05) whereas the B-specific IgG
response was comparable in both age groups (0.122 ±
0.006 and 0.125 ± 0.012, in young versus elderly). These
responses were lower than the H1N1 response and there-
fore we didn’t measure the subclasses specific for these
antigens.
Age effects on in vitro cell mediated immunity
To understand if the IgG1/IgG3 production was associ-
ated with a particular cytokine profile, we then measured
H1N1-induced T cell cytokine production in H1N1-
stimulated PBMC cultures. H1N1 was the only antigen
able to stimulate T cell cytokine secretion in cultures of
PBMC. We measured IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-
10 and Blys and we correlated these with the IgG1 and
IgG3 serum levels at t7 and t28. We found significant
positive correlations only between TNF-α and IL-6 and
IgG3 levels at t28 (Figure 3). A positive trend was ob-
served between IL-10 and IgG3 levels, but it was border-
line of significance (p = 0.058). Conversely, Blys and
IgG3 levels showed a negative trend, which was not sta-
tistically significant (p = 0.38). All correlations and p
values are in Table 2. These results indicate that IgG3
production is associated with a pro-inflammatory cyto-
kine profile. For T cells, production of pro-inflammatory
cytokines in response to a vaccine is beneficial. There-
fore, the suboptimal response with IgG3 here could be
compensated by a better T cell response to the vaccine
and would be protective for the individual.
Immunosenescence is associated with a low grade
chronic pro-inflammatory status called inflammaging
[27]. We can hypothesize that increased levels of pro-
inflammatory mediators with age will induce predomin-
antly the release of IgG3 antibodies which last for a
shorter time as compared to IgG1 antibodies and there-
fore will be less protective than IgG1. However, this was0.0 0.2 0.4 0.6 0.8 1.0
0
10000
20000
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50000
p=0.0001
H1N1-specific IgG3
ositively correlated with levels of serum H1N1-specific IgG3.
thawed and cultured with H1N1 (2 μg), for 3 days. At the end of this
ction. Correlations were calculated by Pearson’s test, using GraphPad
dividuals are given in Table 1.
Table 2 Correlations between cytokine production in
H1N1-stimulated PBMC cultures and serum IgG3 levels
Cytokine in supernatants IgG3 (t7)
Person’s r
p IgG3 (t28)
Person’s r
p
TNF-α 0.0861 0.58 0.3545 0.0006
IL-6 0.2264 0.31 0.4556 0.0001
IL-10 0.3120 0.09 0.3963 0.06
IFN-γ 0.1623 0.96 0.1918 0.91
IL-4 0.0215 0.56 0.0467 0.49
IL-5 0.0484 0.43 0.0513 0.40
Blys −0.1604 0.16 −0.1528 0.38
PBMC (106 cells/ml) were isolated from the peripheral blood at t0, thawed and
cultured with H1N1 (2 μg), for 3 days. At the end of this time, supernatants
were collected and analyzed in ELISA for cytokine production. Correlations
were calculated by Pearson’s test, using GraphPad Prism 5 software.
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http://www.immunityageing.com/content/10/1/14not the case during the 2011-2012 flu season, due to the
fact that H1N1 was not a new antigen and every individ-
ual had a protective titer at t0. In future vaccination sea-
sons in which a new antigen will be part of the vaccine,
it will be necessary to evaluate whether inflammaging
will induce the release of robust IgG3 production and
whether these antibodies will be effective in protecting
individuals at risk from infection with influenza viruses.
AID is also positively correlated with IgG3
We have recently identified B cell-specific biomarkers
which can be used to predict the in vivo response to the
influenza vaccine. The enzyme AID is one of our chosen
markers because we have previously shown that it com-
pletely correlates with the ability of human B cells to un-
dergo CSR [38] and affinity maturation of Ig genes [39].
We measured AID mRNA expression induced by CpG
in the same individuals as above. The CpG response was
measured at t0, as we have shown that this can predict
the robustness of the in vivo vaccine response [34]. Re-
sults in Figure 4 show that AID mRNA expression in0.0 0.1 0.2 0.3 0.4 0.5
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Figure 4 CpG-induced AID at t0 and the serum response are correlate
t0, were thawed and cultured with CpG, for 3 days. At the end of this time
as raw qPCR values (ΔCt) of AID mRNA normalized to GAPDH. Correlations
calculated using GraphPad Prism 5 software. Pearson’s r = 0.4086 (left) and
of individuals are given in Table 1.response to CpG at t0 significantly correlates with the
in vivo response measured by H1N1-specific serum
IgG3 as well as IgG1 levels at t7 and this also occurs at
t28 (for IgG3, Pearson’s r = 0.3921, p = 0.035; for IgG1,
Pearson’s r = 0.4025, p = 0.021). These results confirm
our previous evidence that CpG-induced AID measures
the competence of B cells and can effectively predict
the ability of an individual to generate optimal specific
humoral responses, which reflect not only expansion of
previously induced switched memory B cells and ultim-
ately generation of long-lived plasma cells, but also an
ongoing switch process from IgM memory to switched
memory B cells and we have shown herein that IgG3
switch is associated with production of pro-inflammatory
cytokines.
Conclusions
Because of repeated immunizations, the total IgG re-
sponse in the 2011-2012 season to the pandemic (p)
2009 H1N1 strain was an excellent, protective response
for every individual. In fact, the CDC has stated that this
was the year with the lowest incidence of influenza-like-
illnesses. In analyzing this response, our data showed
that the peak of the response was at day 7, suggesting a
memory response. This response was characterized by a
robust induction of IgG3, which is known to have a
shorter half-life than IgG1. Presently, it is not clear what
contributed to this increased IgG3 response, but pre-
sumably components in the vaccine preparation itself. It
is important to know that both IgG1 and IgG3 were in-
creased after vaccination in all individuals, and thus
would have contributed to their protection. In an at-
tempt to explain why there was more IgG3, we mea-
sured in vitro generated T cell cytokines and found that
the H1N1-specific serum IgG3 levels were associated
with TNF-α and IL-6. Both IgG1 and IgG3 responses
were decreased by age and we confirmed that AID0.0 0.1 0.2 0.3 0.4 0.5
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d. Frozen PBMC (106 cells/ml), isolated from the peripheral blood at
, cells were processed as described in Methods. Results are expressed
between CpG-induced AID at t0 and H1N1-specific ELISA were
r = 0.5249 (right). P values are indicated for each graph. The numbers
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http://www.immunityageing.com/content/10/1/14generated in vitro after stimulation is a predictive bio-
marker of not only IgG1 but also IgG3 in vivo vaccine
responses.
Methods
Subjects
Experiments were conducted using blood isolated from
healthy volunteers of different ages after appropriate
signed informed consent and were approved with IRB
protocol #20070481. In every experiment reported in
the present paper, 35 young and 25 elderly individuals
were evaluated. For the purpose of this study, “elderly”
individuals refer to individuals ≥60 years of age. We previ-
ously reported that individuals of this age may be catego-
rized in the “elderly/affected” group [34,35,38,39], as B cell
numbers and functions (antibody production and affinity
maturation) are significantly decreased. Demographic and
serological characteristics of the participants are shown in
Table 1. All subjects were influenza-free at the time of en-
rollment, at the time of blood draws, were without symp-
toms associated with respiratory infections, and did not
contract flu-like symptoms within a 6 month follow-up
period.
Influenza vaccination
The study was conducted during the 2011-2012 seasonal
influenza vaccination. Two Trivalent Inactivated Vaccines
(TIV) were used: Novartis Fluvirin and GSK Fluarix.
Blood samples were collected immediately before vaccin-
ation (t0), one week (t7) and 4-6 (t28) weeks post-vaccin-
ation. The in vivo response to the influenza vaccine was
measured by HAI (Hemagglutination inhibition) assay
and by ELISA.
Hemagglutination inhibition (HAI) assay
We evaluated the response to the influenza vaccine by
fold-increase in the reciprocal of H1N1-specific titers at
t7 divided by that at t0 by HAI assay, as we have previ-
ously described [34,35]. The H1N1 2009 egg-derived
mono-bulk subunit antigen (A/California/07/2009) from
Novartis Vaccines and Diagnostic (Siena, Italy) was used
at the concentration of 2 μg/ml. The H3N2 and B anti-
gens, also from Novartis, were used at the same concen-
tration. The HAI assay is based on the ability of certain
viruses or viral components to hemagglutinate the red
blood cells of specific animal species [40]. Antibodies
specific to influenza can inhibit this agglutination. Paired
pre- and post-immunization serum samples from the
same individual were tested simultaneously. Briefly, sera
were pretreated with receptor destroying enzyme (RDE,
Denke Seiken Co Ltd) for 20 hrs at 37°C; in order to in-
activate this enzyme, sera were then heated at 56°C for
60 min. Two-fold serial dilutions were done; 25 μl of di-
luted sera were incubated with an equal volume of 4 HAunits of the H1N1 antigen, for 1 hr at room temperature
and then 50 μl of a 1.25% suspension of chicken red
blood cells were added. After two hrs of incubation at
room temperature titers were determined. Serum in-
hibiting titers of 1/40 or greater are the defined positive
measure of seroprotection against infection, whereas a
four-fold rise in the reciprocal of the titer from t0 to t28
indicates a positive response to the vaccine and indicates
seroconversion [34,35,40,41]. Because the 2011-2012 sea-
son was the third consecutive one in which the H1N1 was
the pandemic 2009 swine-origin strain, we saw an early
serum response to the vaccine which peaked 7 days after
vaccination. For the same reason, initial titers were ≥1/40
in 94% of the individuals in the study, indicating high
levels of seroprotection.
Enzyme-linked immunosorbent assay (ELISA)
H1N1-specific IgG concentrations in serum of individ-
uals before and after vaccination were evaluated by hu-
man Ig quantitative ELISA kits (Bethyl Labs E80-104).
H1N1-specific IgG1 and IgG3 were measured by human
Ig quantitative ELISA kits (Southern Biotech, 9052-08
and 9210-04, respectively), after coating the plates with
the H1N1 subunit antigen (Novartis), at the concentra-
tion of 2 μg/ml. Results are expressed as follows: OD val-
ues at t7 (or at t28) - OD values at t0.
TNF-α, IL-6 and CRP were also measured by ELISA kits
(Life Technologies KHC3013, KHC0062 and KHA0032).
CMV serostatus was determined by ELISA using the
CMV-IgG-ELISA PKS assay (Medac), which measures
serum CMV-specific IgG antibody levels.
IFN-γ, TNF-α, IL-4, IL-5, IL-6 and IL-10 were measured
by human ELISA kits (Life Technologies KHC4121,
KHC3013, KHC0043, KHC0052, KHC0063, KHC0103,
respectively). Blys was measured by the hypersensitive
ELISA kit (adipoGen AG-45B-0001-KI01).
PBMC cultures
PBMC were collected by density gradient centrifugation
using Vacutainer CPT tubes (BD 362761). Cells were
then washed and cryopreserved (frozen) with 90% fetal
bovine serum and 10% DMSO. Frozen PBMC (106) were
processed and stimulated for 1-3 days with H1N1 at the
concentration of 2 μg/106 cells to evaluate T cell cyto-
kine production or with CpG (1 μg/106 cells) to evaluate
AID mRNA expression. For H1N1 as well as for the
other antigens (data not shown) this is the best stimulat-
ing dose generating optimal responses. At the end of
stimulation, cells were harvested, supernatants collected
for ELISA tests and RNA extracted for quantitative (q)
PCR to evaluate AID and GAPDH mRNA expression.
Although B cells in the PBMC cultures have been stimu-
lated in the presence of other cell types, primarily T cells
and monocytes, our endpoint is to measure a B cell
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and we have previously established that purified B cells
give similar results as do PBMC to evaluate effects of
aging on the vaccine response [34].
RNA extraction and quantitative (q)PCR
mRNA was extracted from stimulated PBMC (106 cells),
using the μMACS mRNA isolation kit (Miltenyi Biotec)
and qPCR performed as described [34,35]. Primers are
from Life Technologies.
Statistical analyses
Non-parametric analyses of the variables were performed
by Mann-Whitney test (two-tailed), whereas correlations
were performed by Pearson test, using GraphPad Prism 5
software.
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